RBBP4/RbAp48 Antibody (968701) [Alexa Fluor® 532]

• Applications: WB, IHC
• Clone: 968701
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 532

RBBP4/RbAp48 Antibody (968701) [Alexa Fluor® 532] Summary

• Immunogen: E. coli-derived recombinant human RBBP-4
  Ala2-Ser425
  Accession # 09028
• Specificity: Detects human RBBP-4 in direct ELISAs and Western blots.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

RBBP4 (Retinoblastoma-Binding Protein 4; also RbAp48 and CAF-1) is a 48-56 kDa member of the WD Repeat RBAP46/48/MSI1 family of proteins. It is ubiquitously expressed, and acts as a transcriptional repressor. At the start of G1 of the cell cycle, Rb (retinoblastoma protein) normally associates with an E2F transcription complex on E2F responsive genes, blocking E2F activity. At the appropriate time, Rb is phosphorylated, causing its dissociation from E2F and resulting in E2F activation. Dephosphorylated Rb apparently mediates transcriptional repression by recruiting a histone deacetylase (HDAC), followed by HDAC binding to RBBP4. RBBP4, being a histone-binding protein, now brings histones plus HDACs together, resulting in histone deacetylation and gene silencing. Human RBBP4 is 425 amino acids (aa) in length. It contains six WD repeats (aa 122-403), two N-terminal acetylation sites, and two serine phosphorylation sites at positions 110 and 146. There are at least two isoform variants. One contains a six aa substitution for aa 405-425, while another utilizes an alternative start site at Met36. Human and mouse RBBP4 are identical in aa sequence.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.